Saci Nivo Rela for TNBC

This is a randomized, open-label, phase Ib study to assess safety and efficacy of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus a fixed dose combination of nivolumab and relatlimab in patients with any programmed cell death-ligand 1 (PD-L1) status metastatic, triple negative breast cancer on routine testing with one prior line of cytotoxic chemotherapy with or without immunotherapy in the metastatic setting. The study treatment will be continued until the progression of disease, unacceptable toxicity, death, or withdrawal of consent for any reason.

Trial Details

NCT ID
NCT06963905
Phase
PHASE1 / PHASE2
Sponsor
Yale University
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Relatlimab FDC + Nivolumab
  • Sacituzumab Govitecan (SG)
  • Nivolumab
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816

Key Eligibility Criteria

  • Must be competent and able to comprehend, sign, and date an IRB approved ICF before the performance of any study specific procedures or tests.
  • Participants 18 years or older.
  • Pathologically documented breast cancer that:
  • Is defined as unresectable/metastatic disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →